| Drug Study | OXA/FOX | PEN | TET | TMP/SXT | ERY | CLN | GEN | CIP | RIF | LZD | VAN |
| [13] (n = 364) | 21% | NR | NR | 19% | 35% | NR | 0.8% | 18% | NR | NR | 0.5% |
| [19] (n = 86) | 7% | 75.6% | 21% | 44% | NR | 2% | 8% | 7% | 7% | NR | NR |
| [14] (n = 82) | 84.1% | NR | NR | 75.6% | 81.7% | 37.8% | 84.1% | 74.4% | NR | NR | 0 |
| [16] (n = 71) | 46.5% | NR | 29.6% | 45.5% | 47.9% | 8.5% | 38% | 36.6% | NR | 1.4% | 1.4% |
| [22] (n = 731) | 3.7% | 92.2% | 15.5% | 42.1% | 11.9% | 10% | 1.9% | NR | 0.4% | NR | NR |
| [15] (n = 39)* | 36.5% | NR | 92% | NR | 92% | 87% | 77% | 72% | 90% | 23% | 26% |
| [23] (n = 944) | 28% | 92% | 33% | 57% | 26% | 7% | 13% | NR | 8% | 3% | 5% |
| [21] (n = 62) | 18.9% | 66.1% | 35.5% | 46.8% | 51.6% | NR | 3.2% | 22.6% | NR | 1.6% | 53.2%** |
| [9] (n = 52) | 11% | 98% | 21% | 67% | 17% | 13% | 15% | 13.5% | 11.6% | 0 | 0 |
| [25] (n = 32) | 21% | 100% | 34.3% | 40.6% | 34.3% | 28% | 25% | NR | 37.5% | 0 | 0 |